SUPPLEMENTARY INFORMATION

MULTIPLE CAPSID PROTEIN BINDING SITES MEDIATE

SELECTIVE PACKAGING OF THE ALPHAVIRUS GENOMIC RNA

Brown et al.



Supplementary Figure 1. SFV/Cp mAVI virus is comparable to SFV/Cp WT. Related to Figure 1. (a) Single-step growth curve comparing SFV WT vs. mAVI. Cells were infected at an MOI=10 and the media collected at the indicated time points and titered by plaque assay. Individual points from n=2 biological replicates are plotted. Source data are provided as a Source Data file. (b) Transmission electron microscopy of Vero BirA cells infected for 7.5 h with SFV WT (upper) or SFV mAVI (lower). Scale bar represents 200 nm. Black arrows denote NCs of budding viral particles, white arrowheads denote budded viral particles, and black arrowheads denote cellular NCs. The images are representative examples from n=1 experiment. (c) Immunofluorescence of Vero cells mock infected or infected with SFV WT or SFV mAVI for 7.5 h and stained with a monoclonal antibody against Cp. Scale bar represents 10 µm. The images are representative examples from n=2 biological replicates. (d) Immunofluorescence of Vero BirA cells infected with SFV WT or SFV mAVI for 7.5 h and stained with a monoclonal antibody against Cp (green), a polyclonal antibody against E2/E1 (blue), and a Streptavidin Alexa-568 probe (red). Scale bar represents 10 µm. The images are representative examples from n=2 biological replicates. (e) The lysates from Figure 1B were analyzed by western blot using a polyclonal antibody to envelope proteins E2/E1 and a polyclonal antibody to tubulin. The images are representative examples from n=2 biological replicates. Source data are provided as a Source Data file. (f) PAR-CLIP was performed on Vero BirA cells mock infected or infected with SFV mAVI. SA-DBretrieved samples were ³²P-end labeled and either mock treated or treated with Proteinase K, RNaseA, or DNaseI to identify the nature of the lower band (asterisk). The lower band is a UV-independent (Figure 1e) and proteinaceous species. The image represents n=1 experiment. Source data are provided as a Source Data file.



Supplementary Figure 2. PAR-CLIP sample preparation. Related to Figures 2 and 5. (a) Nucleotide composition of the genome (gRNA), the top 58 Cp binding sites, the top 21 Cp binding sites, and the sites never bound by Cp (zero reads). (b) Vero cells were infected at an MOI=10 with SFV mAVI and incubated with 4SU. At 7 hpi, cells were UV irradiated or mock irradiated, lysed, processed, and the cellular NCs were fractionated by 7.5-20% (wt/wt) sucrose gradient sedimentation. Aliquots of each fraction were subjected to SDS-PAGE and western blot analysis using a polyclonal antibody to Cp and a Streptavidin Alexa-680 probe. Cellular NC fractions (red) were pooled, denatured with 0.5% SDS, and then incubated with SA-DB to isolate CpxRNA complexes. The images are representative examples from n=2 biological replicates. Source data are provided as a Source Data file. (c) Cp PAR-CLIP libraries from the total cellular, cellular NC, and viral NC populations were generated using similar starting protein concentrations. 5% of each of the SA-DB-retrieved samples was analyzed by western blot using a monoclonal antibody to Cp and a Streptavidin Alexa-680 probe. Samples are from the same gel/blot, but the lanes were rearranged post-image acquisition for lane consistency and therefore a black line was added between cellular and viral NC. The images represent n=2 independent experiments. Source data are provided as a Source Data file.

a GLAM2 motif analysis of top 21 and top 58 binding sites.

NAME	START	SITES	END	STRAND	MARGINAL SCORE
1	11	cgg.gtcg	17	+	1.53
2	16	tgg a gttg	23	+	8.50
3	16	tggtgttg	23	+	8.87
4	5	tgctgttc	12	+	6.53
5	9	gg caactc	16	+	3.38
6	25	tggccttg	32	+	6.26
7	10	g g g a g <mark>c</mark> g g	17	+	1.65
8	11	tgg. a ttg	17	+	5.53
9	11	ggccgctg	18	+	7.67
10	11	t gc.g ttt	17	+	1.30
11	10	tgctgctg	17	+	7.96
12	15	tg c tattg	22	+	7.51
13	5	ggccgtcg	12	+	6.23
14	5	tgg a gttg	12	+	8.50
15	23	g g g . g <mark>c c</mark> g	29	+	2.97
16	37	tg acac tg	44	+	4.72
17	3	tgccgtcc	10	+	4.89
18	24	ggg.attc	30	+	2.52
19	11	cgac gttg	18	+	3.64
20	7	gggt ac tg	14	+	6.09
21	14	tgcccctg	21	+	5.35

Cp's top 21 sites. Best Motif Found:

Score: 81.8401



GLAM2 (no SSC) 20.06.19 13:31

Cp's top 58 sites. Best Motif Found:

NAME	START	SITES	END	STRAND	MARGINAL SCORE
1	4	tgg.ttg. ac ggg.t. c g	17	+	3.01
2	10	c gg. c tg.tggag.t.tg	23	+	12.2
3	4	aag.cgtcgggtt.tg	17	+	5.58
4	8	tgttctccaactt.tg	22	+	6.36
6	19	<pre>cag.tgg.tggcc.t.tg</pre>	32	+	5.38
7	3	tgt.acacgggag.cg	16	+	1.21
8	11	tgg.att.gggtt.tg	23	+	4.23
9	23	cgg.cctggac.cccg	36	+	7.41
11	5	tta.cttgctg.c.tg	17	+	1.27
13	4	agg.ccg.tcggcac.ca	18	+	3.67
14	11	tga.cctggacag.tg	24	+	10.4
15	16	agg.cttgggggc.cg	29	+	5.21
16	32	cgt.ctt.gacac.tg	44	+	8.73
17	6	cgtccgg.tcatctt.tg	21	+	4.56
18	3	cgc.cgt.gac.g.ta	14	+	1.13
19	5	cga.cgtcgacgt.tg	18	+	11.2
20	29	tga.ctc.cgc.c.tg	40	+	2.47
21	22	cgt.cgg.agcac.g.tg	35	+	7.75
22	7	tg a.c ttgg ac .t.gg	19	+	4.73
24	15	tgctctg.tacac.t.cg	29	+	5.01
25	5	cga.ttg.tggccgt.cg	19	+	5.45
26	17	cgttcgtcatc.c.cg	30	+	2.89
28	24	tgt.cctggacac.tg	37	+	11.5
31	11	cgt.cgt.tcgag.g.tg	24	+	5.00
32	17	cgg.ctg.c.gcctg.tg	30	+	6.40
34	6	tga.cgtacac.cctg	19	+	5.01
35	5	tga.ctg.t.atctt.cg	18	+	3.91
36	9	ttg.cgcccggat.tg	22	+	2.69
38	7	cgg.ccg.aagactt.tg	21	+	9.35
39	2	agttccg.tggacgc.tg	17	+	9.65
40	23	cgc.ccg.tgg aa .c.tg	36	+	4.94
41	7	aac.ataggactg.tg	20	+	0.690
42	41	tgg.agg.ccgag.c.tg	54	+	7.83
43	17	cgc.cgtacggatctg	31	+	3.01
45	8	cgttcgg.c.gactt.tg	22	+	8.80
46	6	tac.ctgctggac.t.tg	20	+	5.57
48	1	tat.ccg.cggtcgt.cg	15	+	5.54
52	9	tta.cgg.ccgccgg.tg	23	+	4.75
53	15	tgg.actcggcag.tg	28	+	6.94
54	4	tgt.cgg.tggtcacctg	19	+	11.1
55	2	caa.cgcggac.c.tg	14	+	6.96
57	41	tgg.agg.ccgag.c.tg	54	+	7.83
58	10	cag.cgg.a.gccat.tg	23	+	4.82

Score: 145.701





b mFold secondary structure predictions of top 21 binding sites.



c Comparison of different mFold secondary structure predictions for site #1.







e mFold secondary structure predictions of SFV PS WT vs. Mutant.



Supplementary Figure 3. Sequence and structural motif analyses for Cp's top binding sites. Related to Figures 2 and 6. (a) GLAM2 was used with its default settings to discover potential gapped sequence motifs within Cp's top 21 and top 58 binding sites. (b) RNA secondary structure predictions for Cp's top 21 binding sites using mFold under default settings. Input sequence was the exact sequence identified as the binding site. Genome nucleotide positions are labeled. Blue arrows indicate tandem G:U wobble base pairs present in sites #1, 2, 8, 14, and 15. (c) mFold secondary structure predictions for site #1 RNA using different input sequences: the exact sequence identified as the binding site (middle), and -/+20 nt from the Constinked most frequently (right). (d) As in (c) but for site #2 RNA. (e) RNA secondary structure prediction for the WT PS sequence (nt:2726-2991) (left) compared to the mutated sequence of the Full PS mutant (right). Blue numbers mark the Cp-PS binding site's 5' and 3' ends.

а

a	
Overall Site 1	sequence identity between SFV and CHIKV_AF15561 is ${\sim}67\%$
27/29 <mark>93</mark> %	
AF15561	ACATGGTTGACGGGTCGGATAGTTGCTTG ACATGGTGGACGGGTCGGAGAGTTGCTTG ****** ************
Site 2 21/30 <mark>70%</mark>	
SFV AF15561	ACATGAGGACGGCTGTGGAGTTGCTCAATG AGATGCGGACCCAAGTGGAGCTGCTGGATG * *** **** *****.****.***
Site 3 20/28 <mark>71%</mark> SFV AF15561	AGGAAGCGTCGGGTTTGGTGTGGTGGG AAGAAGCTGCAGGACTGGTACTGGTGGG
	* * * * * * * * * * * * * * * * * * * *
Site 4 15/22 <mark>68%</mark> SFV AF15561	TTCTTGCTGTTCTCCAACTTTG TTTTTCCTATTTAGCAATTTTG
	** ** ** ** ** ***
Site 5 12/22 54. SFV AF15561	5% AAAC-TCGGGGCAACTCATATTG GGACGTAGGAGATGTTCAAAGTG ** * **.**** * **
Site 6 23/32 <mark>728</mark> SFV AF15561	; <mark>AGGACAGAGCTTACTCTCCAGTGGTGGCCTTG</mark> AAGACAAAGCATACTCACCCGAAGTAGCCCTG * **** *** **** ** * ** **
Site 7 11/20 55% SFV AF15561	ATTGTACACGGGAGCGGACG ACTGTATTTAATGGCAGAGACCCCG *.******.** **
Site 8 17/23 <mark>748</mark> SFV	AACGGCGTATTGGATTGGGTTTG
17E T J J O T	* * * * * * * * * * * * * * * *
Site 9 30/40 <mark>758</mark> SFV	TTCATATTCGGGCCGCTGTCATCGGCCTGGACCCCGTTCG
AF15561	TTCATTGTGGGGCCAATGTCTTCAGCCTGGACACCTTTTG

Site IU	
11/19 58%	
SEV	
AF15561	* ***** **
SFV	· · · · · · · · · · · · · · · · · · ·
AF15561	ATCTCCTTCGGAGCACCAAG
	* **
Site 11	
15/21 <mark>/1%</mark>	
SFV AF15561	TCACTTACTTGCTGCTGCTTG ACACTAACCTGCTGCTGTTG
111 10001	**** ** ********
Site 12	
12/22 55%	
SFV	AAATTCAACCAGGCTGCTATTG
af15561	CGTTTTCACCAGACGGCAGTGG
	· ^ · · ^ · ^ · ^ · ^ · · · ·
Site 13	
16/24 67%	
SFV	ATCAG-GCCGTCGGCACCATATAAG
AF15561	ATTCGCCCCGCCTGC-CCATACAAA
	** * *** * ** ********
SILE 14 30/42 719	
JU/42 /10	
SFV	
SFV AF15561	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG
SFV AF15561	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG *****.** **.**.******** **.***. ***
SFV AF15561	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG *****.** **.**.******** **.**. ***
SFV AF15561 Site 15	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG *****.** **.**.******* **.**. ***. ***
SFV AF15561 Site 15 16/29 55%	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG *****.** **.**.******* **.**. ***
SFV AF15561 Site 15 16/29 55% SFV AF15561	CAAGTGGCTACCGGACAGGCCTGGGCCGA CAAGTGGCTCCGGACAGGCCTGGGGGCCGA CAGATGGCAACGGACAGGCCTGGGGGCCGA
SFV AF15561 Site 15 16/29 55% SFV AF15561	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG *****.** **.**.***********************
SFV AF15561 Site 15 16/29 55% SFV AF15561	CAAGTGGTTCCGGACAGGGCTAGGGCCGA CAAGTGGTTCCGGACAGGGCTTGGGGGCCGA CAGATGGCAACGAACAGGGCTTAGATGA ****. **.***** .**
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG ***** ** **.**.******** **.***. *** CAAGTGGTTCCGGACAGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTAATAGATGA *****. **.**** .** .**
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66%	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTCTGCCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG ****** ** **.**.******** **.**********
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV DE15561	ACTATGGAGTTGACCTGGACAGTGGCCTGTTTTTTGGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG ***** **.** CAAGTGGTTCCGGACAGGCTTGGGGGGCCGA CAAGTGGCAACGAACAGGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTAATAGATGA *****. **** CTACCTGTACGCACTCCTCGGATTTCGGCGGCGTCTTGACACTG CTACCTGTACGCACTCCTCGGATTTCGGCGGCGTCTTGACACTG
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561	CAAGTGGTTCCGGACAGGGCTAGGGCCGA CAAGTGGTTCCGGACAGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTAATAGATGA *****. **.****** .** .** CTACCTGTACGCACTCCTCGGATTTCGGCGGCGTCTTGACACTG CAGCCTGCACCCACTCCTCAGACTTTGGGGGGCGTAGCCATCATT * **** ** ******* ** ** ** ** ** ** **
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561	ACTATGGAGTTGACCTGGACAGTGGGCTGTTTTTTGGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCCGACCAGTGGGTGG
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17	CAAGTGGTTCCGGACAGTGGGCTGTTTTCTGCCCCG ***** ** **.**.***********************
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52%	ACTATGGAGTTGACCTGGACAGTGGGCTGTTTTTTGGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCCGA ****** **** CAAGTGGTTCCGGACAGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTAATAGATGA ***** ***** ***** ***** ** CTACCTGTACGCACTCCTCGGATTTCGGCGGCGTCTTGACACTG CAGCCTGCACCCACTCCTCAGACTTTGGGGGGCGTAGCCATCATT * .***** ** .***** * .*****
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV	ACTATEGAGTTGACCTEGACAGTEGECTETTTTCTGECCCCG TGTATEGGGGTGGATCTAGACAGTEGGCCTATTCTCTAAACCG *********************************
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV AF15561	ACTATEGGAGTTGACCTEGGACAGTGGCCTGTTTTCTGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG *********************************
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV AF15561	CAAGTGGGTTCCGGACAGGCTTGGGGGGCCGA CAAGTGGGTTCCGGACAGGCTTGGGGGGCCGA CAAGTGGCTTCCGGACAGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTAATAGATGA *****. ****. *** .** CTACCTGTACGCACTCCTCGGATTTCGGCGGCGTCTTGACACTG CAGCCTGCACCCACTCCTCAGACTTTGGGGGGCGTAGCCATCATT *****. **. ************************
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV AF15561 Site 18	CAAGTGGGTTCCGGACAGGCTTGGGGGGCCGA CAAGTGGGTTCCGGACAGGCTTGGGGGGCCGA CAAGTGGCTTCCGGACAGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTAATAGATGA *****. ***** .** .** CTACCTGTACGCACTCCTCGGATTTCGGCGGCGTCTTGACACTG CAGCCTGCACCCACTCCTCGGATTTCGGGGGGCGTAGCCATCATT * .****. ** ************** ******* *. *.
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV AF15561 Site 18 24/34 71%	CAAGTGGTTCCGGACAGTGGGCTATTGTCTGAAACCG ****** *****************************
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV AF15561 Site 18 24/34 71% SFV	CAAGTGGTGGACCTGGACAGGGGGGCCGA CAAGTGGTTCCGGACAGGGCTTGGGGGGCCGA CAGATGGCAACGAACAGGGCTTAGAGAGGA *****. **.***** .** .** CTACCTGTACGCACCCCTCGGATTTCGGCGGCGTCTTGACACTG CAGCCTGCACCCACTCCTCGGATTTCGGGGGCGTAGCCATCATT * .**** .** ******** .** .** .** .** .*
SFV AF15561 Site 15 16/29 55% SFV AF15561 Site 16 28/44 66% SFV AF15561 Site 17 11/21 52% SFV AF15561 Site 18 24/34 71% SFV AF15561	CAAGTGGATCAGGACAGTGGCCTGTTTTCTGGCCCCG TGTATGGGGTGGATCTAGACAGTGGGCTATTCTCTAAACCG ****** ** ***************************

Site 19 17/21 <mark>81%</mark> SFV AF15561	TCGACGTCGACGTTGAAG TCGAAATCGACGTGGAAC **** .****** ***
Site 20 26/40 65% SFV AF15561	CAAGCAGGGTACTGGAGCAGAGACTCACTGACTCCGCCTG CTAGCCGGGTGTTGGAAGATCGTCTGACAAAATCCGCATG * *** *******. * * ** ** .* *****
Packaging Seque	ence Binding Site

Site 21	
24/35 <mark>69%</mark>	
SFV	AAAATCCCTTGTATGCCCCTGCGTCGGAGCACGTG
AF15561	AAAACCCACTCTATGCATCAACATCAGAGCACGTC
	**** ** * ***** * * **********

b

Full Packaging Sequence 197/266 74% SFV ACCACAGGACAGACCAAGCCCAGGAGACATCGTGTTAACATGCTTCCGAGGCTGGG AF15561 ACTACAGGCTCAACGAAACCTGACCCTGGAGACCTCGTGTTAACGTGCTTCAGAGGGTGGG TAAAGCAGCTGCAGTTGGACTACCGTGGACACGAAGTCATGACAGCAGCAGCATCTCAGGG SFV AF15561 TTAAACAACTGCAAATTGACTATCGTGGACACGAGGTCATGACAGCAGCCGCATCCCAAGG SFV AF15561 GTTAACTAGAAAAGGAGTTTACGCAGTTAGGCAAAAAGTTAACGAAAACCCACTCTATGCA SFV CCTGCGTCGGAGCACGTGAATGTACTGCTGACGCGCACTGAGGATAGGCTGGTGGGAAAA AF15561 TCAACATCAGAGCACGTCAACGTACTCCTAACGCGTACGGAAGGTAAACTGGTATGGAAGA SFV CGCTGGCCGGCGATCCCTGGAT AF15561 CACTCTCTGGTGACCCGTGGAT

Supplementary Figure 4. Sequence alignments between SFV and CHIKV. Related to Figures 2 and 4. Multiple sequence alignment (MUSCLE)¹ was used to align the SFV and CHIKV genome sequences. (a) The top 21 SFV Cp binding sites aligned with the corresponding CHIKV sequences. Sequences highlighted in yellow are hyperconserved between SFV and CHIKV compared to the overall sequence identity (~67%) between SFV and CHIKV genomes. (b) The SFV full PS (nt:2726-2991) aligned with the corresponding CHIKV sequence. The sequence is highlighted in yellow because it is hyperconserved.



Supplementary Figure 5. Purified Cp and Cp ELISA. Related to Figure 6. (a) 300 ng of purified 2xStrep-tagged Cp was subjected to SDS-PAGE and Coomassie staining. The gel is representative of n=5 independent purifications. Source data are provided as a Source Data file. (b) ELISA signals corresponding to different Cp treatment conditions. A 2-fold dilution series of Cp was incubated either 30% sucrose, or 30% sucrose and 1% SDS plus boiling for 5 min before diluting in binding buffer. Individual absorbance readings from technical duplicates are plotted. Lines represent linear regression. ELISA signals between the various treatments were comparable and linear (R²>0.98) within the same protein range (~1-12.5 ng). The graph is representative of n=2 independent experiments. Source data are provided as a Source Data file.

Supplementary References

1. Madeira, F. *et al.* The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids Res* **47**, W636-w641 (2019).